Humana Inc vs Rocket Companies Inc. Class A Common Stock — how do they compare? Humana Inc trades at $427.5 (market cap $50.48B), while Rocket Companies Inc. Class A Common Stock trades at $10.6 (market cap $30.67B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.84% dividend while Rocket Companies Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| HUM | RKT | |
|---|---|---|
Market Cap | $50.48B | $30.67B |
Volume | 1,889,709 | 41,104,143 |
Sector | Health | Financials |
52-Week High | $433.50 | $23.44 |
52-Week Low | $163.67 | $10.53 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $57.83B | $60.66B |
Dividend Yield | 0.84% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $427.59, down 1.36% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is robust, reaching $129.66 billion in 2025, though net income margins have compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and strong institutional buying interest, while the company prepares for Q3 earnings on November 6.
The stock offers upside to the $469.89 consensus target but faces risks from margin pressure and regulatory scrutiny. Earnings beats in recent quarters support momentum, yet profitability trends and Medicare Advantage plan changes require monitoring for sustained growth.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →